Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | 0.00% | +9.52% |
04-17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
04-17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Business Summary
Number of employees: 17
Managers
Managers | Title | Age | Since |
---|---|---|---|
Tiffany Thorn
FOU | Founder | 37 | 31/12/15 |
Adrian Howd
DFI | Director of Finance/CFO | 52 | 02/10/23 |
Simon Wallwork
SEC | Corporate Secretary | - | 21/06/21 |
Oliver Schon
PRN | Corporate Officer/Principal | - | 13/09/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Kauffman
CHM | Chairman | 60 | 15/01/22 |
William Paris
BRD | Director/Board Member | 73 | 21/09/21 |
Susan Lowther
BRD | Director/Board Member | 65 | 21/09/21 |
Tiffany Thorn
FOU | Founder | 37 | 31/12/15 |
Robert Hawkins
BRD | Director/Board Member | 69 | 21/09/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 82,526,088 | 52,278,670 ( 63.35 %) | 0 | 63.35 % |
Company contact information
BiVictriX Therapeutics Plc
Mereside Alderley Park Alderley Edge
SK10 4TG, Macclesfield
+
http://www.bivictrix.comSector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 11.88M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- BVX Stock
- Company BiVictriX Therapeutics Plc